Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study).
Dimitrios RigopoulosEleftheria TampouratziCharalampos AngelakopoulosZoi ApallaIoannis BarkisSophia GeorgiouFlorentina DelliAlexandros DrososEfterpi ZafiriouJohn KatsantonisElisabeth LazaridouPantelis PanagakisEvangelina PapadavidMarkos PapakonstantisAngeliki-Viktoria Roussaki-SchulzeElena SotiriouGeorgios AnastasiadisVasiliki ChasapiKonstantinos SfaelosDemetrios Ioannidesnull nullPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Brodalumab confers rapid and durable responses, as well as improvements in the quality of life of moderate-to-severe psoriasis patients.
Keyphrases
- end stage renal disease
- ejection fraction
- randomized controlled trial
- early onset
- chronic kidney disease
- high intensity
- newly diagnosed
- coronary artery disease
- peritoneal dialysis
- electronic health record
- big data
- drug induced
- artificial intelligence
- patient reported outcomes
- deep learning
- quantum dots
- loop mediated isothermal amplification
- sensitive detection